Phase II Construction of NCNPR Research Wing

NCNPR研究楼二期建设

• 批准号: 7877557
• 负责人: LARRY A WALKER
• 金额: $ 1391.54万
• 依托单位: UNIVERSITY OF MISSISSIPPI
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2015-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7877557
• 关键词: Advanced Development; Area; Award; Basic Science; Biological Factors; Botanicals; Clinical Research; Commit; Development; Drug Delivery Systems; Drug Formulations; Floor; Fostering; Foundations; Funding; Health; Human; Laboratories; Mechanics; Mississippi; Molecular Mechanisms of Action; Pharmacologic Substance; Phase; Production; Request for Applications; Research; Research Project Grants; Safety; Technology; Therapeutic; Time; Toxic effect; Translations; Universities; Wing; analog; base; commercialization; design; dietary supplements; drug development; economic impact; falls; good laboratory practice; marine natural product; microbial; programs; scale up; symposium

DESCRIPTION (provided by applicant): The objective of this project is the completion of the construction of the University of Mississippi's National Center for Natural Products Research (NCNPR) Phase II research wing. This will entail addition of the top two floors, with completion of a portion of the first floor of this research wing, with a total of about 55,000 gross SF of new research space. Note that funds are already committed for the construction of the basement and substantial completion of the first floor; this is slated to begin in fall 2009, with an anticipated completion date in early 2011. This application requests funds to construct the second and third floors, and partial build-out for completion of the first floor, of the Phase II research wing as envisioned in the original NCNPR planning and in the Phase II facility programming document. This proposed project, if awarded, can be timed so as to be completed in concert with the currently funded component as a single, continuous construction. At the foundation of this NCNPR program are a number of PHS and other federally funded research projects aimed at discovery, design, and synthesis of new drugs and development of new drug delivery systems for unmet therapeutic needs in human health, an important national priority. Early development activities to facilitate commercialization of these technologies will also be a critical function for this program. Such efforts are key components for realization of the full potential economic impact of these natural product-based discoveries. In addition, the NCNPR has a strong and growing research effort to expand the scientific basis for enhancement of the authentication, quality and safety of botanical products used as dietary supplements in the US. Completion of this construction as planned will foster translation of basic research into clinical studies and commercial development as follows: 1) provide laboratories for scaling up extraction and isolation of bulk natural products in quantities that will support advanced development activities; 2) provide laboratories for scale-up synthesis and analog development; 3) provide Good Laboratory Practice-compliant analytical facilities that will support bioanalytical research, product and regulatory package development; 4) provide Good Manufacturing Practice-compliant facilities for production of active pharmaceutical ingredient (API); 5) provide laboratories for preformulation, formulation and stability studies to characterize APIs; 6) provide laboratories for cellular and molecular mechanism of action and toxicity studies; and 7) provide laboratories for expansion of discovery efforts with greater emphasis on microbial and marine natural products. The requested funding will support construction to include 55,127 gross SF (partial first floor, 7,117; second floor 24,005; third floor, 24,005). Four laboratories of about 860 SF will be included in the first floor section, with eight laboratories each on the second and third floors; laboratory and building/mechanical support areas and office/cubicle/conference spaces are also included on each floor. Total net laboratory, office and support spaces to be constructed with this requested funding on the three floors will be 23,011 SF of new laboratory space, 9,773 SF of new office space, and 15,460 SF in support areas.

描述（由申请人提供）：本项目的目标是完成密西西比大学国家天然产物研究中心（NCNPR）第二阶段研究翼的建设。这将需要增加最高两层，并完成该研究翼一楼的一部分，总共约55，000平方英尺的新研究空间。请注意，已为地下室的建造和一楼的基本完工承付了资金;这项工作定于2009年秋季开始，预计完工日期为2011年初。该申请要求提供资金，以建造第二和第三层，并部分扩建完成第一层，第二阶段的研究翼，在最初的NCNPR规划和第二阶段设施规划文件中设想。这一拟议项目如果获得批准，可以安排时间，以便与目前供资的部分一起作为一个单一的连续建筑完成。在这个NCNPR计划的基础上，有一些PHS和其他联邦资助的研究项目，旨在发现，设计和合成新药，并开发新的药物输送系统，以满足人类健康的治疗需求，这是一个重要的国家优先事项。促进这些技术商业化的早期开发活动也将是该计划的关键功能。这些努力是实现这些基于自然产品的发现的全部潜在经济影响的关键组成部分。此外，NCNPR有一个强大的和不断增长的研究工作，以扩大科学基础，提高认证，质量和安全的植物产品用作膳食补充剂在美国。按计划完成这一建设将促进基础研究转化为临床研究和商业开发，具体如下：1）提供实验室，用于按比例扩大大量天然产品的提取和分离，以支持先进的开发活动; 2）提供实验室，用于按比例扩大合成和类似物开发; 3）提供符合药物非临床研究质量管理规范的分析设施，以支持生物分析研究、产品和监管包装的开发; 4）提供符合良好生产规范的设施，用于生产活性药物成分（API）; 5）提供实验室，用于预配制、配制和稳定性研究，以表征API; 6）提供实验室进行细胞和分子作用机制和毒性研究; 7）提供实验室扩大发现工作，更加重视微生物和海洋天然产品。所要求的资金将用于支持包括毛额55 127平方英尺的建筑（部分一楼7 117平方英尺;二楼24 005平方英尺;三楼24 005平方英尺）。一楼部分将包括四个约860平方英尺的实验室，二楼和三楼各有八个实验室;每层还包括实验室和建筑/机械支持区以及办公室/隔间/会议空间。利用所申请的资金在三层楼建造的实验室、办公室和支助空间的总净面积为23，011平方英尺的新实验室空间、9，773平方英尺的新办公空间和15，460平方英尺的支助区域。